HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

BACKGROUND: The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and the safety of the biologically active HIV-1 Tat protein administered at 7.5 or 30 μg, given 3 or 5 times monthly, and at explorin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ensoli, Fabrizio, Cafaro, Aurelio, Casabianca, Anna, Tripiciano, Antonella, Bellino, Stefania, Longo, Olimpia, Francavilla, Vittorio, Picconi, Orietta, Sgadari, Cecilia, Moretti, Sonia, Cossut, Maria R Pavone, Arancio, Angela, Orlandi, Chiara, Sernicola, Leonardo, Maggiorella, Maria T, Paniccia, Giovanni, Mussini, Cristina, Lazzarin, Adriano, Sighinolfi, Laura, Palamara, Guido, Gori, Andrea, Angarano, Gioacchino, Di Pietro, Massimo, Galli, Massimo, Mercurio, Vito S, Castelli, Francesco, Di Perri, Giovanni, Monini, Paolo, Magnani, Mauro, Garaci, Enrico, Ensoli, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414440/
https://www.ncbi.nlm.nih.gov/pubmed/25924841
http://dx.doi.org/10.1186/s12977-015-0151-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414440/
https://www.ncbi.nlm.nih.gov/pubmed/25924841
http://dx.doi.org/10.1186/s12977-015-0151-y

Ejemplares similares